[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT04262830":3,"trial-entities:NCT04262830":110,"trial-summary:NCT04262830":114},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":22,"study_type":23,"primary_purpose":24,"phases":25,"enrollment_info":26,"interventions":29,"primary_outcomes":40,"secondary_outcomes":45,"sex":46,"minimum_age":47,"maximum_age":48,"healthy_volunteers":15,"eligibility_criteria":49,"std_ages":60,"locations":63,"central_contacts":94,"overall_officials":101,"references":104,"see_also_links":109},"NCT04262830","181758","Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure","CATCH-HF: Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure","RECRUITING","2030-09-30","2025-01","2025-01-28","2019-09-30","Hari Narayan","OTHER",false,"Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.","Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.\n\nCardiac remodeling, function, and tissue characteristics will be examined using cardiac MRI in combination with other research assessments to assess the cardiotoxic effects of cancer therapy. Analyses will be performed in a cohort of adolescents and young adults with a history of childhood cancer.",[19,20,21],"Cardiotoxicity","Pediatric Cancer","Heart Failure",[],"OBSERVATIONAL",null,[],{"count":27,"type":28},150,"ESTIMATED",[30,36],{"type":31,"name":32,"description":33,"armGroupLabels":34},"DIAGNOSTIC_TEST","Cardiac magnetic resonance imaging (MRI)","Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics",[35],"All Study Participants",{"type":14,"name":37,"description":38,"armGroupLabels":39},"Accelerometer physical activity monitoring","Measurement of physical activity using hip-worn accelerometer.",[35],[41],{"measure":42,"description":43,"timeFrame":44},"Left ventricular ejection fraction (LVEF)","LVEF is an assessment of left ventricular global systolic function.","3 - 5 years",[],"ALL","13 Years","39 Years",{"inclusion":50,"exclusion":54,"raw_text":59},[51,52,53],"English and Spanish speaking male and female subjects, ages 13-39 years old","Diagnosis of cancer at age \\\u003C22 years","Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior.",[55,56,57,58],"Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants.","Medical, psychiatric, and\u002For social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia.","Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus).","Pregnancy (at the time of enrollment).","Inclusion Criteria:\n\n* English and Spanish speaking male and female subjects, ages 13-39 years old\n* Diagnosis of cancer at age \\\u003C22 years\n* Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior.\n\nExclusion Criteria:\n\n* Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants.\n* Medical, psychiatric, and\u002For social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia.\n* Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus).\n* Pregnancy (at the time of enrollment).",[61,62],"CHILD","ADULT",[64],{"facility":65,"status":8,"city":66,"state":67,"zip":68,"country":69,"contacts":70,"geoPoint":91},"Rady Children's Hospital","San Diego","California","92123","United States",[71,76,81,83,86,88,89],{"name":72,"role":73,"phone":74,"email":75},"Hari Narayan, MD","CONTACT","858-966-5855","hnarayan@rchsd.org",{"name":77,"role":73,"phone":78,"phoneExt":79,"email":80},"Maria Teresa Acuero, MAS","8585761700","227139","macuero@rchsd.org",{"name":72,"role":82},"PRINCIPAL_INVESTIGATOR",{"name":84,"role":85},"Dennis Kuo, MD","SUB_INVESTIGATOR",{"name":87,"role":85},"Mark Abcede, MBA",{"name":77,"role":85},{"name":90,"role":85},"Cesar Vasquez, BS",{"lat":92,"lon":93},32.71571,-117.16472,[95,97],{"name":72,"role":73,"phone":96,"email":75},"8589665855 \u002F 8589331718",{"name":98,"role":73,"phone":99,"email":100},"Cesar Vasquez","8589331718","cvasquez2@rchsd.org",[102],{"name":72,"affiliation":103,"role":82},"University of California San Diego, Rady Children's Hospital",[105],{"pmid":106,"type":107,"citation":108},"42499264","DERIVED","Narayan HK, Chen S, Wong FL, Young N, Qi A, Davis C, Hegde S, Gloude N, Leger KJ, Getz KD, Contijoch F, Ness K, Ky B, Kuo D, Hartman SJ, Armenian SH. The Relationship Between Physical Activity and Left Ventricular Remodeling in Childhood Cancer Survivors Treated With Anthracyclines: A Cross-Sectional Study. Pediatr Blood Cancer. 2026 Jul 25:e70523. doi: 10.1002\u002F1545-5017.70523. Online ahead of print.",[],{"nct_id":4,"conditions":111,"biomarkers":113},[19,112],"Childhood Malignant Neoplasm",[],{"nct_id":4,"found":115,"summary":116,"prompt_version":126},true,{"design":117,"status":118,"heading":119,"summary":120,"follow_up":121,"word_count":122,"commitments":123,"compensation":124,"drugs_mentioned":125},"This is an observational study, meaning researchers will monitor participants without providing new treatments. It plans to enroll 150 participants.","completed","Cardiotoxicity Assessment in Pediatric Cancer Survivors","This observational study is looking at how to better identify heart problems (cardiotoxicity) in young people who had cancer as children. Many childhood cancer survivors were treated with medicines like doxorubicin or daunorubicin, which can sometimes lead to heart failure later in life. Researchers will use heart imaging (cardiac MRI) and physical activity monitoring to find early signs of heart damage. The goal is to develop better ways to diagnose and treat these heart issues before they become serious. You may be able to join if you are 13-39 years old, had cancer before age 22, and were treated with anthracycline therapy at least two years ago. The study aims to enroll 150 participants.","The main heart function measurement (Left ventricular ejection fraction) will be assessed at 3-5 years.",114,"Participants will undergo cardiac magnetic resonance imaging (MRI) and wear a hip-worn accelerometer to measure physical activity. Not specified in the trial record.","Not stated in the trial record.",[],"v2"]